| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:ARNTL2_STK38L |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: ARNTL2_STK38L | KinaseFusionDB ID: KFG443 | FusionGDB2.0 ID: KFG443 | Hgene | Tgene | Gene symbol | ARNTL2 | STK38L | Gene ID | 56938 | 23012 | |
| Gene name | basic helix-loop-helix ARNT like 2 | serine/threonine kinase 38 like | ||||||||||
| Synonyms | ARNTL2|CLIF|MOP9|PASD9|bHLHe6 | NDR2 | ||||||||||
| Cytomap | 12p11.23 | 12p11.23 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | basic helix-loop-helix ARNT-like protein 2CYCLE-like factorPAS domain-containing protein 9aryl hydrocarbon receptor nuclear translocator like 2basic-helix-loop-helix-PAS protein MOP9brain and muscle ARNT-like 2class E basic helix-loop-helix protein | serine/threonine-protein kinase 38-likeNDR2 protein kinasenuclear Dbf2-related 2nuclear Dbf2-related kinase 2 | ||||||||||
| Modification date | 20240403 | 20240305 | ||||||||||
| UniProtAcc | Q8WYA1 | Q9Y2H1 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000261178, ENST00000266503, ENST00000311001, ENST00000395901, ENST00000544915, ENST00000546179, ENST00000539558, ENST00000542388, | ENST00000389032, ENST00000539577, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: ARNTL2 [Title/Abstract] AND STK38L [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ARNTL2(27486036)-STK38L(27450643), # samples:1 STK38L(27397265)-ARNTL2(27568802), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ARNTL2 | GO:0006357 | regulation of transcription by RNA polymerase II | 12055078 |
| Hgene | ARNTL2 | GO:0007623 | circadian rhythm | 10864977 |
| Hgene | ARNTL2 | GO:0032922 | circadian regulation of gene expression | 10864977 |
| Hgene | ARNTL2 | GO:0042753 | positive regulation of circadian rhythm | 12738229 |
| Hgene | ARNTL2 | GO:0045893 | positive regulation of DNA-templated transcription | 10864977|12738229 |
| Hgene | ARNTL2 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 15147242 |
| Tgene | STK38L | GO:0006468 | protein phosphorylation | 15037617 |
| Tgene | STK38L | GO:0006468 | protein phosphorylation | 15067004 |
| Tgene | STK38L | GO:0010507 | negative regulation of autophagy | 35670107 |
| Tgene | STK38L | GO:0035556 | intracellular signal transduction | 15067004 |
| Kinase Fusion gene breakpoints across ARNTL2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across STK38L (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-63-A5MP-01A | ARNTL2 | chr12 | 27486036 | STK38L | chr12 | 27450643 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:27486036/:27450643) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ARNTL2 | STK38L |
| FUNCTION: Transcriptional activator which forms a core component of the circadian clock. The circadian clock, an internal time-keeping system, regulates various physiological processes through the generation of approximately 24 hour circadian rhythms in gene expression, which are translated into rhythms in metabolism and behavior. It is derived from the Latin roots 'circa' (about) and 'diem' (day) and acts as an important regulator of a wide array of physiological functions including metabolism, sleep, body temperature, blood pressure, endocrine, immune, cardiovascular, and renal function. Consists of two major components: the central clock, residing in the suprachiasmatic nucleus (SCN) of the brain, and the peripheral clocks that are present in nearly every tissue and organ system. Both the central and peripheral clocks can be reset by environmental cues, also known as Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the central clock is light, which is sensed by retina and signals directly to the SCN. The central clock entrains the peripheral clocks through neuronal and hormonal signals, body temperature and feeding-related cues, aligning all clocks with the external light/dark cycle. Circadian rhythms allow an organism to achieve temporal homeostasis with its environment at the molecular level by regulating gene expression to create a peak of protein expression once every 24 hours to control when a particular physiological process is most active with respect to the solar day. Transcription and translation of core clock components (CLOCK, NPAS2, BMAL1, BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a critical role in rhythm generation, whereas delays imposed by post-translational modifications (PTMs) are important for determining the period (tau) of the rhythms (tau refers to the period of a rhythm and is the length, in time, of one complete cycle). A diurnal rhythm is synchronized with the day/night cycle, while the ultradian and infradian rhythms have a period shorter and longer than 24 hours, respectively. Disruptions in the circadian rhythms contribute to the pathology of cardiovascular diseases, cancer, metabolic syndromes and aging. A transcription/translation feedback loop (TTFL) forms the core of the molecular circadian clock mechanism. Transcription factors, CLOCK or NPAS2 and BMAL1 or BMAL2, form the positive limb of the feedback loop, act in the form of a heterodimer and activate the transcription of core clock genes and clock-controlled genes (involved in key metabolic processes), harboring E-box elements (5'-CACGTG-3') within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form the negative limb of the feedback loop and interact with the CLOCK|NPAS2-BMAL1|BMAL2 heterodimer inhibiting its activity and thereby negatively regulating their own expression. This heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G, which form a second feedback loop and which activate and repress BMAL1 transcription, respectively. The CLOCK-BMAL2 heterodimer activates the transcription of SERPINE1/PAI1 and BHLHE40/DEC1. {ECO:0000269|PubMed:11018023, ECO:0000269|PubMed:12738229, ECO:0000269|PubMed:14672706}. | FUNCTION: Involved in the regulation of structural processes in differentiating and mature neuronal cells. {ECO:0000250, ECO:0000269|PubMed:15037617, ECO:0000269|PubMed:15067004}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of ARNTL2_STK38L |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| STK38L | Q9Y2H1 | human | IRF3 | Q14653 | S396 | NtVDLHIsNsHPLsL | |
| STK38L | Q9Y2H1 | human | NUAK1 | O60285 | T211 | QKDKFLQtFCGSPLY | Pkinase |
| STK38L | Q9Y2H1 | human | RAB3IP | Q96QF0 | S288 | KGHTRNKstSSAMSG | |
| STK38L | Q9Y2H1 | human | YAP1 | P46937 | S127 | PQHVRAHssPAsLQL | |
| STK38L | Q9Y2H1 | human | ULK1 | O75385 | S495 | GVLARKMsLGGGRPY | |
| STK38L | Q9Y2H1 | human | STK38L | Q9Y2H1 | S282 | NRRQLAYstVGtPDy | Pkinase |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| STK38L | ID | Description | 0.00e+00 |
| STK38L | GO:0031345 | negative regulation of cell projection organization | 6.69e-03 |
| STK38L | GO:0120033 | negative regulation of plasma membrane bounded cell projection assembly | 1.02e-02 |
| STK38L | GO:0001959 | regulation of cytokine-mediated signaling pathway | 4.20e-02 |
| STK38L | GO:0060759 | regulation of response to cytokine stimulus | 4.20e-02 |
| STK38L | GO:0031099 | regeneration | 4.20e-02 |
| STK38L | GO:0120032 | regulation of plasma membrane bounded cell projection assembly | 4.20e-02 |
| STK38L | GO:0060491 | regulation of cell projection assembly | 4.20e-02 |
| STK38L | GO:0042594 | response to starvation | 4.20e-02 |
| STK38L | GO:1902115 | regulation of organelle assembly | 4.20e-02 |
| STK38L | GO:0060560 | developmental growth involved in morphogenesis | 4.20e-02 |
| STK38L | GO:0031669 | cellular response to nutrient levels | 4.20e-02 |
| STK38L | GO:0034727 | piecemeal microautophagy of the nucleus | 4.20e-02 |
| STK38L | GO:0060245 | detection of cell density | 4.20e-02 |
| STK38L | GO:0031668 | cellular response to extracellular stimulus | 4.20e-02 |
| STK38L | GO:0033148 | positive regulation of intracellular estrogen receptor signaling pathway | 4.20e-02 |
| STK38L | GO:0035666 | TRIF-dependent toll-like receptor signaling pathway | 4.20e-02 |
| STK38L | GO:0039530 | MDA-5 signaling pathway | 4.20e-02 |
| STK38L | GO:0048671 | negative regulation of collateral sprouting | 4.20e-02 |
| STK38L | GO:0050847 | progesterone receptor signaling pathway | 4.20e-02 |
| STK38L | GO:1903059 | regulation of protein lipidation | 4.20e-02 |
| STK38L | GO:0018105 | peptidyl-serine phosphorylation | 4.20e-02 |
| STK38L | GO:0033145 | positive regulation of intracellular steroid hormone receptor signaling pathway | 4.20e-02 |
| STK38L | GO:0072182 | regulation of nephron tubule epithelial cell differentiation | 4.20e-02 |
| STK38L | GO:0018209 | peptidyl-serine modification | 4.20e-02 |
| STK38L | GO:0016237 | lysosomal microautophagy | 4.20e-02 |
| STK38L | GO:0048638 | regulation of developmental growth | 4.20e-02 |
| STK38L | GO:0071888 | macrophage apoptotic process | 4.20e-02 |
| STK38L | GO:0072160 | nephron tubule epithelial cell differentiation | 4.20e-02 |
| STK38L | GO:0048368 | lateral mesoderm development | 4.20e-02 |
| STK38L | GO:0071496 | cellular response to external stimulus | 4.20e-02 |
| STK38L | GO:0030522 | intracellular receptor signaling pathway | 4.20e-02 |
| STK38L | GO:0010506 | regulation of autophagy | 4.20e-02 |
| STK38L | GO:0002756 | MyD88-independent toll-like receptor signaling pathway | 4.20e-02 |
| STK38L | GO:2000696 | regulation of epithelial cell differentiation involved in kidney development | 4.20e-02 |
| STK38L | GO:0050746 | regulation of lipoprotein metabolic process | 4.20e-02 |
| STK38L | GO:0071360 | cellular response to exogenous dsRNA | 4.20e-02 |
| STK38L | GO:0060271 | cilium assembly | 4.20e-02 |
| STK38L | GO:0048339 | paraxial mesoderm development | 4.20e-02 |
| STK38L | GO:0060576 | intestinal epithelial cell development | 4.20e-02 |
| STK38L | GO:0061709 | reticulophagy | 4.20e-02 |
| STK38L | GO:0001829 | trophectodermal cell differentiation | 4.20e-02 |
| STK38L | GO:0030903 | notochord development | 4.20e-02 |
| STK38L | GO:0044804 | nucleophagy | 4.20e-02 |
| STK38L | GO:0060602 | branch elongation of an epithelium | 4.20e-02 |
| STK38L | GO:2000786 | positive regulation of autophagosome assembly | 4.20e-02 |
| STK38L | GO:0050767 | regulation of neurogenesis | 4.20e-02 |
| STK38L | GO:0060340 | positive regulation of type I interferon-mediated signaling pathway | 4.20e-02 |
| STK38L | GO:1902018 | negative regulation of cilium assembly | 4.20e-02 |
| STK38L | GO:0044782 | cilium organization | 4.20e-02 |
Top |
Related Drugs to ARNTL2_STK38L |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning ARNTL2-STK38L and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to ARNTL2_STK38L |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |